Table 1.
Mutations | Number of patients with mutations detected by Invader screening (n=384) | Variant alleles detected by Invader screening (n=768) | Variant alleles detected by MPS (n=768) | Variant alleles detected by direct sequencing (n=768) |
---|---|---|---|---|
GJB2:NM_004004:c235delC:p.L79fs | 42 (10.9%) | 52 (6.8%) | 52 | 52 |
GJB2:NM_004004:c.109G>A:p.V37I | 19 (4.9%) | 21 (2.7%) | 21 | 21 |
GJB2:NM_004004:c.[134G>A; 408C>A]:p.[G45E; Y136X] | 16 (4.2%) | 17 (2.2%) | 18b | 17 |
GJB2:NM_004004:c.427C>T:p.R143W | 13 (3.4%)a | 13 (1.7%)a | 15b | 14 |
GJB2:NM_004004:c.176_191del16:p.59_64del | 9 (2.3%) | 10 (1.3%) | 10 | 10 |
GJB2:NM_004004:c.257C>G:p.T86R | 5 (1.3%) | 6 (0.8%) | 6 | 6 |
GJB2:NM_004004:c.299_300del:p.100_100del | 6 (1.6%) | 6 (0.8%) | 6 | 6 |
SLC26A4:NM_000441:c.2168A>G:p.H723R | 15 (3.9%) | 20 (2.6%) | 20 | 20 |
SLC26A4:NM_000441:c.1229C>T:p.T410M | 4 (1.0%) | 6 (0.8%) | 6 | 6 |
SLC26A4:NM_000441:c.1174A>T:p.N392Y | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.367C>T:p.P123S | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.2162C>T:p.T721M | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.601-1G>A:Splicing | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.916dupG:p.I305fs | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.1648dupT:p.R549fs | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
SLC26A4:NM_000441:c.919-2A>G:Splicing | 1 (0.3%) | 1 (0.1%) | 0c | 1 |
CRYM:NM_001888:c.941A>C:p.K314T | 1 (0.3%) | 1 (0.1%) | 1 | 1 |
Mitochondria 1555A>G | 5 (1.3%) | — | — | — |
Mitochondria 3243A>G | 8 (2.1%) | — | — | — |
Mitochondria 8296A>G | 1 (0.3%) | — | — | — |
c.427C>T mutation was not detected by Invader screening in one case (reason unknown).
MPS misgenotyped heterozygous as homozygous mutations in one case each because of the other mutations located in the AmpliSeq primer region (see details in main text).
c.919-2A>G mutation was located in the region not covered by AmpliSeq primers.
MPS, massively parallel DNA sequencing.